Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Vertex's HCV Drug VX-950 Gets Fast Track

December 9, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

On Thursday, Vertex Pharmaceuticals Inc. announced the Food and Drug Administration has granted its hepatitis C drug "fast track" status, which formalizes agency assistance in drug development and in-process data submissions. FDA grants fast track designation, which can speed up the review process, to therapies that address an unmet need. Vertex's VX-950 therapy, which is in mid-stage human trials, has the potential to shorten the time hepatitis C patients spend on medication, the company said.

Back to other news for December 9, 2005

Adapted from:
Associated Press
12.08.2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development

Tools
 

Advertisement